Imaging company Lantheus enters therapeutics with Progenics takeout

Lantheus plans to acquire Progenics in an all-stock deal, creating a path for the medical imaging company to move into therapeutics.

Based on the 86.4 million outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE